A sudden increase in Stevens-Johnson syndrome-a rare and potentially fatal skin disorder-may be triggered by COVID-19, increased vaccination rates, or a lowered threshold caused by vaccines or previous infection, according to a large case series recently published in the medical journal Burns.
Of the 14 reported cases, five patients had COVID-19 a month before developing SJS/TEN, and three of 14 patients received a COVID-19 vaccine one month prior.
Of the three cases attributed to vaccination in the study, two patients had received an mRNA vaccine, and one received a viral vector vaccine within a month of developing SJS/TEN. Researchers identified eight other cases of SJS following COVID-19 vaccination in published literature-four were associated with mRNA vaccines, three with viral vector vaccines like AstraZeneca and Johnson & Johnson, and one with a whole virus vaccine.
Historically, VAERS has been shown to report fewer than 1 percent of actual vaccine adverse events, which means other cases of SJS/TEN may have occurred but were unreported.
A 26-year-old male received two previous doses of a viral vector vaccine and one mRNA vaccine dose.
A 53-year-old female received a viral vector vaccine three weeks before the onset of SJS/TEN. She was quadruple vaccinated with viral vector and mRNA vaccines and reacted to medications received for a life-threatening scleroderma complication.
Regulatory agencies in the United States and abroad have not acknowledged the potential link between SJS/TEN and COVID-19 vaccines or studied the ability of the virus or vaccine to prime the immune system.
No comments:
Post a Comment